ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Dyclonine: Drug information

Dyclonine: Drug information
(For additional information see "Dyclonine: Patient drug information" and see "Dyclonine: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Pharmacologic Category
  • Local Anesthetic, Oral
Dosing: Adult
Cough and mouth/throat symptoms

Cough and mouth/throat symptoms: Oral topical: Lozenge: Slowly dissolve 1 lozenge in mouth every 2 hours as needed (maximum: 10 lozenges/day).

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Dyclonine: Pediatric drug information")

Mouth/throat symptoms

Mouth/throat symptoms: Approved ages varies by product; product-specific dosing:

Lozenge 2 mg: Children ≥6 years and Adolescents: Oral topical: Slowly dissolve one lozenge in mouth every 2 hours as needed; maximum daily dose: 10 lozenges/day

Lozenge 2 mg (with menthol 5 mg and pectin 6 mg): Children ≥4 years and Adolescents: Oral topical: Slowly dissolve one lozenge in mouth every 2 hours as needed; maximum daily dose: 10 lozenges/day

Lozenge 3 mg (with menthol 6 mg): Children ≥4 years and Adolescents: Oral topical: Slowly dissolve one lozenge in mouth every 2 hours as needed; maximum daily dose: 10 lozenges/day

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

Frequency not defined.

Central nervous system: Feeling hot, localized numbness, localized warm feeling, sensation of cold

Gastrointestinal: Burning sensation of mouth

Hypersensitivity: Hypersensitivity reaction

Local: Local irritation, local pain

Warnings/Precautions

Other warnings/precautions:

• Self-medication (OTC use): When used for self-medication (OTC), discontinue use and contact health care provider if sore throat is severe, lasts >2 days, or occurs with or following fever, headache, rash, nausea, or vomiting; sore mouth symptoms lasting for >7 days; irritation, pain, or redness persists or worsens; or swelling, rash or fever develops; cough lasts >7 days, comes back, or occurs with fever or persistent headache. Consult a health care provider before use for cough that lasts or is chronic (eg, cough that occurs with smoking, asthma, emphysema) or cough that occurs with too much mucous.

Dosage forms specific issues:

• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer's labeling.

• Tartrazine: Some formulations may contain FD&C yellow #5 (tartrazine), which may cause allergic-type reactions (including bronchial asthma) in susceptible individuals, particularly those with aspirin sensitivity.

Warnings: Additional Pediatric Considerations

Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, >3,000 mg/day), or topically have been associated with potentially fatal toxicities, which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).

Generic Equivalent Available: US

Yes

Administration: Adult

Oral: Allow lozenge to slowly dissolve in mouth.

Administration: Pediatric

Topical: Allow lozenges to slowly dissolve in mouth.

Use: Labeled Indications

Cough: Temporary relief of cough associated with a cold or inhaled irritants (when used in combination with menthol).

Mouth/throat symptoms: Temporary relief of occasional mouth and throat symptoms (eg, minor irritation, pain, sore throat and sore mouth); protection of irritated areas in sore mouth and throat.

Medication Safety Issues
Sound-alike/look-alike issues:

Dyclonine may be confused with dicyclomine

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. Risk C: Monitor therapy

Mechanism of Action

Local anesthetic that produces reversible loss of sensation by preventing or diminishing the conduction of nerve impulses near application site.

  1. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
  2. Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. Pediatr Crit Care Med. 2009;10(2):256-259. [PubMed 19188870]
  3. Sucrets Sore Throat (dyclonine) [prescribing information]. Langhorne, PA: Insight Pharmaceuticals; received May 2017.
  4. Sucrets Sore Throat & Cough (dyclonine) [prescribing information]. Langhorne, PA: Insight Pharmaceuticals; received May 2017.
  5. Sucrets Sore Throat, Cough & Dry Mouth (dyclonine) [prescribing information]. Langhorne, PA: Insight Pharmaceuticals; received May 2017.
  6. Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. Semin Dial. 2007;20(3):217-219. [PubMed 17555487]
Topic 9397 Version 87.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟